Lilly's Verzenio® prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment 17 October
Lilly confirms date and conference call for third-quarter 2025 financial results announcement 16 October
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes 15 October
